[bioundgrd] Monday, May 10th - Biomatrix/BUSA Lunch with Barry Greene

[Janice Chang]

>Date: Fri, 07 May 2010 00:08:15 -0400
>From: Dima Ter-Ovanesyan <dter at MIT.EDU>
>Subject: Biomatrix/BUSA Lunch with Barry Greene
>
>
>Biomatrix and Biology Undergraduate Student Association (BUSA) Present:
>
>Leaders in the Life Science Industry Lunch Series
>
>Lunch with Barry Greene, President and COO at Alnylam Pharmaceuticals
>
>Learn about leading a cutting-edge biotech company developing RNAi 
>Therapeutics
>(Alnylam was originally founded by MIT biology professors Phillip Sharp and
>David Bartel)
>
>Date: Monday, May 10, 2010
>Time:  12:00-1:00 PM
>Room: 68-180
>
>Open to undergrads of all majors.
>
>Space is limited. RSVP to kiner at mit.edu
>
>
>Bio:
>Barry Greene joined Alnylam in September 2003, and brings over 20 years of
>experience in healthcare, pharmaceutical, and biotechnology industries. Prior
>to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals,
>Inc., where he led the company's global strategy and execution for 
>its oncology
>business including strategic business direction and execution, culminating in
>the successful approval and launch of VELCADE? (bortezomib) in mid 2003.
>Prior to joining Millennium in February 2001, Mr. Greene served as Executive
>Vice President and Chief Business Officer for Mediconsult.com. Prior to
>Mediconsult.com, Mr. Greene's past experiences include Vice President of
>Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice
>President Strategic Integration with responsibility for the AstraZeneca North
>American post merger integration; and Partner, Andersen Consulting responsible
>for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene
>received his B.S. in Industrial Engineering from University of Pittsburgh and
>serves as Senior Scholar at Duke University, Fuqua School of Business. Barry
>also serves on the Board of Acorda Therapeutics, Inc. and Regulus 
>Therapeutics,
>LLC.